Limited options for the treatment of prostate cancer have spurred the search for new therapies. One innovative approach is the use of targeted alpha therapy (TAT) to inhibit cancer growth, using an alpha particle emitting radioisotope such as 213 Bi. Because of its short range and high linear energy transfer (LET), aparticles may be particularly effective in the treatment of cancer, especially in inhibiting the development of metastatic tumors from micro-metastases. Prostatespecific membrane antigen (PSMA) is expressed in prostate cancer cells and the neovasculature of a wide variety of malignant neoplasms including lung, colon, breast and others, but not in normal vascular endothelium. The expression is further increased in higher-grade cancers, metastatic disease and hormonerefractory prostate cancer (PCA). J591 is one of several monoclonal antibodies (mabs) to the extracellular domain of PSMA. Chelation of J591 mab with 213 Bi forms the alpha-radioimmunoconjugate (AIC). The objective of this preclinical study was to design an injectable AIC to treat human prostate tumors growing subcutaneously in mice. The anti-proliferative effects of AIC against prostate cancer were tested in vitro using the MTS assay and in vivo with the nude mice model. Apoptosis was documented using terminal deoxynucleotidyl transferase [TdT]-mediated deoxyuridinetriphosphate [dUTP] nick end-labeling (TUNEL) assay, while proliferative index was assessed using the Ki-67 marker. We show that a very high density of PSMA is expressed in an androgen-dependent human PCA cell line (LNCaP-LN3) and in tumor xenografts from nude mice. We also demonstrate that the AIC extensively inhibits the growth of LN3 cells in vitro in a concentration-dependent fashion, causing the cells to undergo apoptosis. Our in vivo studies showed that a local AIC injection of 50 mCi at 2 days post-cell inoculation gave complete inhibition of tumor growth, whereas results for a nonspecific AIC were similar to those for untreated mice. Further, after 1 and 3 weeks post-tumor appearance, a single (100 mCi/100 ml) intra-lesional injection of AIC can inhibit the growth of LN3 tumor xenografts (volume < 100 mm 3 ) in nude mice. Tumors treated with AIC decreased in volume from a mean 46 AE 14 mm 3 in the first week or 71 AE 15 mm 3 in the third week to non-palpable, while in control mice treated with a non-specific AIC using the same dose, tumor volume increased from 42 to 590 mm 3 . There were no observed side effects of the treatment. Because of its in vitro cytotoxicity and these anti-proliferative properties in vivo, the 213 Bi-J591 conjugate has considerable potential as a new therapeutic agent for the treatment of prostate cancer.
Introduction
Each year some 185 000 new cases of prostate cancer are reported in the USA, with 39 000 deaths. 1 Prostate cancer is the second most common cause of death from cancer in men after lung cancer. Radiation prostatectomy or external beam radiation gives the best chance of a cure in patients and achieves a life expectancy of at least 10 y at diagnosis. 2 Survival is a function of the disease being organ confined, specimen confined or margin positive with failure rates of 12, 30 and 60% respectively. So in spite of the most aggressive therapy, a significant percentage of men will die of disseminated disease. 3 Furthermore, radical therapy can have extremely distressing side effects ranging from surgical mortality, incontinence, impotence, bowel damage and stricture. 4 The major problem with the management of prostate cancer is our inability to inhibit the development of metastases that eventually result in death of the patient. Prostate cancer is a very slow growing cancer, and early dissemination of cancer cells occurs before the disease becomes clinical. Because of the difficulty in identifying which 'early' prostate cancers will go on to metastasize, the situation often exists where most patients are treated with radical therapy, resulting in complications and frequently an unacceptably poor quality of life. 3 Thus there is an urgent need for a therapy that can kill cancer cells in transit or at the preangiogenic stage.
Systemic therapy of metastatic prostate cancer is limited to androgen deprivation, for which 80% of patients will show clinical improvement. However, objective tumor regression is seen in only 2 -3% of patients. Almost inevitably, an androgen-independent clone will appear with median time to progression of 12 -18 months. At that stage there is no curative therapy available for metastatic prostate cancer and median survival is about 1 y. 5 Endocrine therapy is palliative, improving the quality of life but not extending life. 6 An alternative palliative approach is the use of bone-seeking radiopharmaceuticals such as 89 Sr and 153 Sm. These isotopes exchange with the Ca component of hydroxyapatite and concentrate in osteoblastic lesion. They provide palliation for 75 -80% of hormone refractory patients, which indicates that radionuclide therapy targeted to prostate cancer cells could be of value in controlling the development of metastases. Cytotoxic chemotherapy, for example doxorubicin, is poorly tolerated in this age group and is generally found to be ineffective or impractical. Therefore new approaches are needed to selectively target prostate cancer cells.
Alpha emitting radionuclides 7 emit alpha particles with energies up to an order of magnitude greater than most of the beta rays, yet their ranges are two orders of magnitude less as alpha particles have a linear energy transfer (LET) which is about 100 times greater. This is manifested by a high relative biological effectiveness (RBE). As a result, a much greater fraction of the total energy is deposited in cells with alphas and very few nuclear hits are required to kill a cell. 8 Consequently, 100-fold enhancement in radiation dose 9, 10 would be delivered to the nucleus of a cancer cell if a 'smart' carrier is employed to take the alpha-radionuclide to that cancer cell. Studies have been carried out on 211 At and 212 Bi 11, 12 with encouraging results. Allen and Blagojevic 7 noted that 149 Tb could be a preferred radiolabel with its superior nuclear decay parameters. Chimeric monoclonal antibodies (mabs) against human glioma and melanoma cells were labeled with 211 At and the cytotoxicity and microdosimetry of the labeled antibodies were measured. 13 Reduction in survival to 0.37 for cells of both human cancer cell lines required an average of only 1 -2 alpha particle hits to the cell nucleus. This work confirms the high cytotoxicity of alpha RIC.
Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein expressed predominantly by prostate cancer cells, which was first identified as a membrane antigen on the prostate cell line LNCaP. While present on normal prostate epithelial cells, it is expressed at generally higher levels on prostate cancer cells. PSMA expression is seen in all prostate cancers and in most metastatic lesions. 14 -18 It is also expressed in prostate cancer in the absence of androgen 14 and is elevated during androgen deprivation therapy. 15 Importantly, PSMA has also been detected in the neovasculature of a wide variety of malignant neoplasms, but not in normal vasculature. 16, 17 This reinforces it as an excellent candidate for targeting, especially in late stage disease. J591 was immunized from BALB/c mice with LNCaP cells. 17 It can detect two distinct extracellular epitopes of PSMA (PSMAext1 and PSMAext2) and is capable of binding viable PSMAexpressing cells. These properties of the J591 mab show it to be a most promising targeting vehicle for the treatment of metastatic prostate cancer.
There are only a few immortalized human prostate cell lines because it is unusually difficult to establish primary cultures or xenografts from surgical specimens of human prostate tumors, even for a short time. 19 PC-3, Du-145, LNCaP and LNCaP-LN3 cell lines are the best characterized cell lines established from metastatic human tumor lesions. 20 -23 The LNCap-LN3 cell line is an androgensensitive and highly metastatic human prostate cancer cell line, which was established from LNCaP. This cell line is a popular model for the study of prostate cancer 22 because it retains some of the most prominent differentiated features of the human prostate cell including the production of the prostate secretory protein, 24 the PSMA, 14 and the androgen receptor. 25 We have reviewed the evidence for targeted alpha therapy (TAT) in detail previously, 26 and in more recent studies, we have produced alpha-radioimmunoconjugates (AICs) for melanoma, 27,28 leukaemia 29 and colorectal cancer, 30 produced and developed 149 Tb as an AIC, 31 and produced 225 Ac at a spallation source, eluting 213 Bi from the Actinium-bismuth Generator. In the present study, we labeled J591 with Bi-213 to investigate TAT of prostate cancer by in vitro and in vivo studies in a nude 
Materials and methods

Production of radioisotopes
The alpha particle emitting radionuclide, 213 Bi, was produced from the 225 Ac/ 213 Bi generator column, purchased from the Department of Energy, USA. 213 Bi was eluted from the 225 Ac column with 250 ml of freshly prepared 0.15 M distilled and stabilized hydriodic acid followed by washing with 250 ml water. A time of 2 h was allowed for 213 Bi to grow back in the generator for next elution.
Radiolabeling procedure
The labeling procedure was that used by Rizvi et al. 27 The chelator, cyclic anhydride of diethylenetriaminepentacetic acid (cDTPAa) was purchased from Aldrich Chemical Company. The buffers were prepared and sterilized in our laboratory. Briefly, cDTPAa was prepared in chloroform and purified under a stream of nitrogen. A chelator: antibody molar ratio of 20:1 was maintained for cDTPAa. After a 45 min on ice incubation of the chelator and J591 mab, the conjugated J591 was measured by plate reader at 280 nm wavelength using ProMax software, and purified on a PD-10 column (Pharmacia Biotech) using 0.5 M sodium acetate at pH 5.5 as the eluting buffer. After 20 min incubation, the labeled antibody was again purified on another PD-10 column using phosphate-buffered saline (PBS) at pH 7.0 as the eluting buffer. The conjugates so obtained were tested for radiolabeling efficiency by Instant Thin Layer Chromatography (ITLC), using Gelman paper (strip size 169 cm) and 0.5 M sodium acetate (pH 5.5) as the solvent. The control AIC was prepared as above but using a non-specific mab (irrelevant isotype IgG2a) against melanoma.
Monoclonal antibodies
The J591 mab against the PSMA was provided by BZL Biologics, USA. The J591 isotype control monoclonal antibody (A2) IgG1 was kindly provided by Department of Microbiology, University of New South Wales. Rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP) was purchased from Dakopatts (Glostrup, Denmark). Goat anti-mouse fluorescein isothiocyanate (FITC) mab was purchased from Silenus (Sydney, NSW, Australia). An anti-Ki67 mouse monoclonal antibody (clone MIB1) was purchased from Immunotech SA, France. Mouse anti-human melanoma IgG2a mab (9.2.27) used as a non-specific control AIC was kindly provided by the Royal Newcastle Hospital, Sydney, Australia for nonspecific AIC.
Cell cultures
LNCaP-LN3 cells were originally obtained from Dr C Pettaway, MD Anderson Hospital, Houston, TX, USA. They were maintained in 1:1 RPMI-1640:F12-K (Life Technologies, Inc., Grand Island, NY, USA), supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) and 1:100 penicillin/streptomycin. Cultures were maintained in a humidified atmosphere of 5% CO 2 at 37 C. The cultures were routinely given fresh medium twice a week, and passaged at pre-confluent densities using a solution of 0.05% trypsin and 0.02% EDTA (Life Technologies, Inc., Grand Island, NY, USA) for subsequent passage. All experiments involved cells that were passaged no more than 10 times.
In vitro MTS assay
To test the cytotoxicity of AIC on LN3 cell growth in vitro, the LN3 cell survival was assessed by the MTS assay. 33 Briefly, after 48 h culture, cells were harvested by rinsing with PBS and detaching with 0.25% trypsin/0.02% EDTA in PBS. Cells were diluted into 96-well plates at a concentration of 5610 4 cells/100 ml in RPMI-1640 plus 5% FCS medium. The activity of 213 Bi-cDTPAa-J591 as specific radio labeled protein conjugate (AIC) and 213 Bi-cDTPAa-9.2.27 antibody as non-specific AIC were checked by radiation activity calibrator immediately before incubation with cells. AIC solution was neutralized to pH 7.0 and four serial doses of specific AIC and nonspecific AIC were incubated with cells in a 5% carbon dioxide atmosphere at 37 C overnight. However, as the half-life of Bi-213 is only 46 min, the effective incubation period is % 2 h. After changing 100 ml new pheno-red free RPMI-1640 medium without the FCS, 20 ml Cell Titer 96 Aqueous One Solution reagent (Promega, WI, USA) was added into each well. After 3 h incubation in a 5% CO 2 atmosphere at 37 C, the absorbance of each well was recorded at 490 nm using an ELISA plate reader after addition of 10% SDS to stop the reaction. The absorbance reflected the number of surviving cells that still have the metabolic capacity in each well. All results were analyzed using Prism software.
Flow cytometry
For the detection of cell-surface expression of PSMA on the LN3 cell line, indirect immunofluorescence staining was performed. Briefly, confluent, adherent cells were harvested by rinsing flasks twice with PBS (pH 7.2) and then detaching with 0.25% trypsin and 0.02% EDTA at 37 C for 5 min. The staining procedure was performed on ice using Dulbecco's phosphate-buffered saline (DPBS) with 5% FBS. Cells (0.5 -1.0610 6 ) were washed twice with 4 ml cold DPBS containing 5% FBS (200 g, 8 min), resuspended in 80 ml of cold DPBS plus 5% FBS, then incubated with either an irrelevant isotype control (A2, IgG1) and DPBS or J591 mab for 30 min on ice in the dark. After washing with DPBS, the cells were resuspended and incubated in goat anti-mouse FITC monoclonal antibody for 30 min. The cells were washed again, resuspended in 0.5 ml of DPBS plus 5% FBS. In all the fluorescence-based experiments, autofluorescence was subtracted. All data Targeted alpha therapy Y Li et al was analysed using CELLQuest software (BectonDickinson).
TUNEL assay for apoptotic cells in vitro
LN3 cells were cultured in 12-well plates and incubated in medium as described above. The cultured cells were treated with AIC in different concentrations (1, 2.5, 5, 10 and 25 mCi) or with non-specific AIC (10 mCi) and without AIC (media alone) at 37 C for overnight. After treatment, cells were washed with PBS, harvested by centrifugation and slides were made by cytospin. Apoptotic cells were detected using the TUNEL method 34 with TdT-fragEL TM in situ apoptotic detection kit according to the manufacturer's instruction (Oncogene Research Products, Boston, MA, USA). Briefly, slides containing LN3 cells were fixed in 4% paraformaldehyde (16PBS, pH 7.4) at room temperature (RT) for 30 min, washed by tris-buffered saline (TBS) and then incubated with 20 mg/ml Proteinase K in 10 mM Tris -HCl, pH 7.4 for 5 min at RT. Following rinsing in TBS, exogenous peroxidases were quenched in 3% hydrogen peroxide for 5 min. After rinsing in TBS, slides were incubated with terminal deoxynucleotidyl transferase (TdT) Equilibration Buffer for 30 min at RT and then incubated with 100 ml of the TUNEL reaction mixture for 1.5 h at 37 C in a humidified atmosphere. Following rinsing in TBS, slides were incubated with 100 ml stop solution at RT for 5 min, pre-diluted 1:50 in blocking buffer and incubated for a further 30 min at RT. After rinsing in TBS slides were incubated with 1 mg/ml DAB substrate (10 mg of 3,3 0 -diaminobenzidene tetrahydrochloride in 10 ml of Tris buffer (pH 7.6) containing 0.03% hydrogen peroxide) and incubated for 10 -15 min at RT. Slides were subsequently washed, counterstained with methylgreen counterstain solution and mounted. Specificity of TUNEL reactivity was confirmed by undertaking in parallel appropriate negative (omitting TdT from the labeling mix) and positive (treated HL-60 slide) controls. Pattern of TUNEL expression was as reported by others. 35 Cells with three or more nuclear chromatin fragments were considered positive for apoptosis. The labeled cells were examined using a Leica light microscope. The results were expressed as a percentage of total cells staining positive for apoptosis.
Animals and inoculation of LN3 cells
Male 8-week-old athymic nude mice, BALB/c (nu/nu), were purchased from Animal Resources Centre (ARC), Western Australia (WA). The mice were housed and maintained under specific pathogen-free conditions in facilities approved by the UNSW ACEC and in accordance with their regulations and standards. All animals were anaesthetized with methoxyfluorane before injection of LN3 cells. To establish s.c. tumors: LN3 cells were dispersed by 0.25% trypsin. After washing in RPMI-1640 plus 5% FBS (8 min centrifugation, 200 g), 2610 6 cells were resuspended in 100 ml of the RPMI-1640 serum-free medium and 100 ml of matrigel (Becton Dickinson, Bedford, MA, USA) and injected via 18-gauge needle into the s.c. space of the right flank region. Because LN3 cells require additional factors or stromal cells, it is necessary to co-inject the cells with matrigel to induce tumor growth in nude mice. 36, 37 Animal treatment protocols Experiment 1 was started 2 days after LN3 cell inoculation with three groups of seven mice; one group was untreated, the other groups were treated with single site injections of non-specific AIC or specific AIC at 50 mCi/ 100 ml. Experiment 2 was started 1 week after tumors appeared when their volumes averaged 46 mm 3 . Three groups of seven mice each received single intralesional injections of AIC at 50 mCi/100 ml, 100 mCi/100 ml or injections of non-specific-AIC at 100 mCi/100ml. Experiment 3 was started 3 weeks after tumors appeared and their volume averaged 74 mm 3 . The treatment protocol was same as for experiment 2 described above. The AIC activity was chosen from our preliminary studies in which various doses were given twice weekly and mice were followed for toxicity, and for which no mice required euthanasia. Tumor progression was documented by measuring volumes once weekly using calipers during the experiments, and their volumes were calculated by the following formula: length6width6height60.52 in millimeters. 38 Data points for both experiments were expressed as average tumor volume AE s.d. of mean based on 4 $ 7 determinations.
Tissues
Mice were killed 1, 3 and 5 weeks after tumor appearance by cervical dislocation while anesthetized by methoxyfluorane. At the end of the experiments, all tumors were collected and routinely checked. Tumor tissue specimens were dissected and prepared as frozen or paraffin sections. For frozen sections, small specimens of approximately 0.2 -0.5 cm 2 of tumor tissue were frozen on dry ice and stored at 770 C. Tissues used for cryostat sectioning were cryoprotected in OCT (Sakura Finetechinical Co, Tokyo, Japan) and mounted on a cryostat specimen holder with liquid nitrogen. Cryostat sections 5 mm thick were cut in a Reichert-Jung cryostat (Cambridge Instruments GmbH, Nussloch, Germany). Cryostat sections were mounted on gelatin-coated glass slides (0.5% gelatin coated microscope slides) and air-dried overnight at RT. One slide was processed immediately and used for routine haematoxin and eosin (H&E) staining and the other slides were stored at 720 C until use. Some mice tissues were immediately put into containers with 10% neutral buffered formalin for paraffin sections. Paraffinembedded tissues were sectioned at 5 mm thickness, mounted on gelatin-coated slides and stained with H&E for routine histological examination, TUNEL apoptosis and other markers.
Immunohistochemistry and apoptosis immunolabeling
An indirect conjugated peroxidase method was used to detect the expression of PSMA or Ki-67 in LN3 cells, frozen sections or paraffin sections from mouse tissues. Confluent LN3 cells were washed with sterile PBS and harvested by 0.25% trypsin and 0.02% EDTA in PBS. Cytospin preparations were made with a Shando Pittsburgh, PA, USA) . Cell cytospins were made on glass slides using 3610 4 cells/60 ml per slide. For PSMA expression staining, slides containing cells or tissue sections were fixed in acetone for 10 min at RT, treated with 3% hydrogen peroxidase in TBS, normal rabbit serum for 10 min and then incubated with mouse anti-human J591 (12.5 mg/ml) for 1 h at RT. After washing with TBS, the slides were subsequently incubated with rabbit anti-mouse IgG-HRP (6.0 mg/ml) for 45 min and then reacted with a freshly prepared DAB substrate solution of 10 mg of 3,3 0 -diaminobenzidene tetrahydrochloride in 10 ml of Tris buffer (pH 7.6) containing 0.03% hydrogen peroxide. Positive cells appear brown. For Ki-67 staining, paraffin sections from tumors were deparaffinized in xylene, followed by a graded series of alcohols (100, 95, and 75%) and re-hydrated in TBS (pH 7.5). After sections were de-paraffinized, slides containing sections were subsequently immersed in boiling 0.01 M solution of citric acid, adjusted to pH 6.0 for 15 min to enhance antigen retrieval, treated with 3% hydrogen peroxidase and then incubated with mouse anti-human Ki-67 monoclonal antibody (1:50 dilution) overnight at 4 C. After that, the same steps were taken to develop the reaction with DAB. The positive cells appear brown in the nucleus. Sections were counterstained with haematoxylin solution for 4 min. Control slides were treated in an identical manner and comprised the isotype monoclonal antibody or the primary antibody omitted as a negative control.
For tumor apoptosis immunolabeling, mice were treated with AIC or with non-specific control AIC. After 3 days, the mice were killed and the tumors were excised for paraffin sections. After de-waxing, fixed sections (5 mm) were stained using the same methods as in vitro for apoptosis (Oncogene Research Products, Boston, MA, USA) except for the incubation of Proteinase K in 10 mM Tris -HCl, pH 7.4 for 20 min at RT.
Quantification of proliferating and apoptotic cells
Tumor tissue sections were mounted with glycerol-gelatin solution (Sigma Chemical Co) for immunostaining cells, with DePex mounting medium (Sigma Chemical Co) for apoptotic cells, and then examined by two independent observers using light microscopy (Leica microscope, Nussloch, Germany) at 640 magnification. The number of proliferating cells and apoptotic cells was assessed by counting the cells with brown stained nuclei positive for Ki-67, or brown stained cells for apoptosis among 500 -1000 cells in randomly chosen fields. A cell is considered Ki-67 positive when it shows nuclear staining, regardless of intensity or pattern. Cytoplasmic staining is not considered positive, while a cell is considered apoptotic when it shows cell shrinkage, nuclear pyknosis, chromatin condensation and blebbing of the plasma membrane. 39 
Results
Expression of PSMA in LN3 cells and tumor
Using J591 anti-PSMA mab, PSMA expression is strongly positive in the LN3 prostate cancer line ( Figure 1A ) in agreement with results published previously, 18 while isotype control staining is negative ( Figure 1B) . Flow cytometry experiments were done with J591 mab in LN3 cell lines to assess the cell avidity. Flow cytometry results (Figure 2) show that the J591 histogram has a strong shift compared with the negative and the isotype controls. These results suggest that J591 receptors are strongly expressed on the cell surface of LN3 cells and provide the basis for AIC treatments for prostate cancer in vitro.
To test PSMA expression in LN3 tumor tissue, frozen sections from mice at 1, 3 and 5 weeks after tumor appearance were stained with J591 mab. The results demonstrated that all tumor cells in all sections are J591 positive while with rare exception, J591 mab bound to tumor-associated neovasculature of prostatic tumors ( Figure 1, C and D) . The staining patterns are in accordance with PSMA expression in human prostate cancer from patients. This result indicates that J591 mab should be useful for in vivo targeting to prostate cancer.
In vitro cytotoxicity
The AIC was prepared with 92% labeling efficiency and tested in vitro for cytotoxicity using the MTS assay. Cell survival experiments with the LN3 cell line show very high cytotoxicity with AIC, but negligible effect for controls as shown in Figure 3 . The D 0 (37% cell survival) value with AIC was calculated to be 4.1 AE 0.2 mCi. At the maximum dose of 10 mCi, cell survival was reduced to 12 -14%, while for the non-specific AIC, cell survival was 90%. AIC inhibits the growth of LN3 cells in vitro in a concentration-dependent fashion. All results were averaged from five experiments performed in triplicate (n ¼ 5).
AIC induced LN3 cell death by apoptosis
One of the mechanisms responsible for the AIC-induced cell death in LN3 cells could be apoptosis. To determine if AIC induces apoptosis, LN3 cells were incubated with increasing concentrations of AIC (1 -10 mCi for 24 h). For an incubation of 5 mCi, 82 AE 8% (mean AE s.d., n ¼ 3) of the cells were TUNEL-positive, compared with 5.3 AE 2.2% (mean AE s.d., n ¼ 3) of the cells receiving non-specific AIC. The free 3 0 ends generated by apoptotic DNA cleavage were detected by TUNEL assay, in which the non-apoptotic cells stained green while apoptotic cells stained brown. The results are shown in Figure 4 , A and B.
In vivo toxicology
Our toxicology studies show that nude mice can tolerate up to 3 mCi/kg of AIC by systemic administration, causing a 5 -10% weight loss. In melanoma bearing mice, up to 10 mCi/kg of anti-melanoma AIC via intra-lesional injection causes about 10% weight loss. 28 These results can be compared with the toxicity of AIC in human patients 40 at the Memorial Sloan Kettering Cancer Institute, when doses up to 1 mCi/kg of 213 Bi-AIC were administered to recurrent acute myelogenous leukaemia patients without serious complications, although myelo- 
In vivo regression of LN3 prostate cancer by local TAT
The s.c. tumor models used in these experiments have the advantage that tumors can easily be directly injected with TAT and that tumor measurements, taken once a week are easy to perform.
(a) Local AIC injection at the inoculation site were made at 2 days post-inoculation. Complete inhibition of tumor growth was observed for the 50 mCi AIC treated group after 10 weeks, while at 3 weeks postinoculation, 6/7 of mice in the no-treatment group and 5/7 of mice in non-specific AIC group had measurable tumors. This results suggests that AIC can completely inhibit the growth of LN3 tumors by targeting and killing isolated cancer cells and cell clusters, preventing tumor genesis. The results are shown in Figure 5A . (b) Nude mice with an established LN3 tumor were randomly divided into three different groups (n ¼ 7) and then treated with either AIC or non-specific AIC. 
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Mean pretreatment LN3 tumor volumes at 1 week post-tumor appearance were 46 AE 14, 44 AE 11 and 43 AE 10 mm 3 for the control, 100 mCi dose of AIC, and 50 mCi dose of AIC groups, respectively. Two weeks after treatment, the volumes in the 100 mCi dose group decreased to non-palpable, while 3 weeks after treatment, the volumes in the 50 mCi dose group decreased to become non-palpable. The volumes in the non-specific control group treated with 100 mCi increased from 46 AE 14 to 487 AE 45 mm 3 10 weeks after treatment. The results are shown in Figure 5B , and demonstrate that compared with nonspecific AIC, both 50 and 100 mCi AIC can specifically target and regress LN3 tumors. (c) At 3 weeks post-tumor appearance, mean pretreatment tumor volumes were 71 AE 15, 76 AE 20 and 73 AE 17 mm 3 for control, 100 mCi and 50 mCi AIC groups, respectively. Three weeks after treatment with 100 mCi AIC, the tumor volumes became nonpalpable while the volumes in the group treated with 50 mCi AIC increased from 73 AE 17 to 167 AE 37 mm 3 . Compared with the control group, 50 mCi can partly inhibit LN3 tumor growth. The results are shown in Figure 5C .
These results indicate that a single local injection of 50 mCi AIC can target and kill isolated metastatic cancer cells and cell clusters, completely inhibiting tumorogenesis. Single intra-lesional injection of 100 mCi AIC can target and completely regress early stage prostate tumors (volume < 100 mm 3 ) while 50 mCi can target and regress smaller tumors (volume < 50 mm 3 ). We also injected large tumors (volume > 200 mm 3 ) with 100 mCi/200 ml and 200 mCi/200 ml. Two weeks after treatment, no tumors had regressed (data not shown).
Toxicity characteristics of systemic AIC such as weight loss, petechiae, listlessness, diarrhea or infection were not observed in any animal during treatment. In two mice treated with AIC, small red wounds could be seen close to the injection point. These wounds were probably caused by AIC complex inhibition of wound healing at the injection site and the wounds soon recovered after treatment. By 10 weeks, there was no evidence of these wounds in any animal.
AIC alters tumor histology and induces apoptosis of LN3 cancer cells in tumors
Histology alterations. To compare the cellular content of each tumor, we harvested tumors from both treated and control groups and stained with H&E. As assessed by light microscope (Figure 4, C and D) , tumors from treated animals ( Figure 4C , 100 mCi AIC after two weeks) were considerably less cellular and were composed primarily of acellular material. In contrast, the tumors from nonspecific AIC control animals ( Figure 4D ) consisted of tightly packed cells, and many blood sinuses were apparent within the tumor. Moreover, the extent of vascularization in treated tumors appeared to be less than in control tumors. Cells were most commonly found in small islands. The results indicated that there was a very large difference in tumor cell burden between treated and control animals.
AIC induced inhibition of cell proliferation in LN3 tumors.
To investigate the effect of AIC on tumor cell proliferation, tumor sections from nude mice were assessed by immunohistochemical localization of Ki-67, which is an indicator of underlying cell DNA synthesis. Antibody against Ki-67 recognizes G 1 , S, G 2 and M phases, but not the G 0 cells out of the cell cycle. 42 AIC treatment after 1 week showed a decrease in volume in LN3 tumors. The decline in tumor volume was associated with a rapid decrease of proliferating Ki-67 expression. A higher percentage of Ki-67 positive tumor cells were observed in non-specific AIC treated mice (43 AE 4%, n ¼ 3), as seen in Figure 4F , whereas only scattered Ki-67 positive cells were detected in AIC treated mice (5.7 AE 1.4%, n ¼ 3), as is evident in Figure 4E . LN3 tumor cells expressed very low proliferative rates after TAT treatment. These data indicate that AIC can regress proliferation of LN3 tumor cells in vivo.
AIC induced apoptosis of xenografts in LN3 tumors
To investigate if the mechanisms involved in the induction of apoptosis in LN3 cell culture represented a phenotypic response of LN3 tumors in vivo, the TUNEL assay was performed at multiple time points from 3 to 7 days after treatment. Representative results are shown in Figure 4 , G and H. There were significantly more apoptotic bodies (20 -25%) in the LN3 tumors treated with AIC ( Figure 4G ) than in the mice treated with control AIC (1 -3%) as shown in Figure 4H . Apoptotic nuclei in the tumors were scattered and located in surrounding tissue of tumors. Central necrosis was observed in all of the tumors, and some distinct apoptotic nuclei were observed in these areas. The apoptotic indices were markedly different between the AIC and non-specific AIC treated mice. This indicates that AIC-induced apoptosis in vitro is similar to that for LN3 tumors.
Discussion
The use of monoclonal antibodies armed with toxins or radionuclides to specifically deliver these cytotoxic agents to tumor cells provides a valuable alternative for cancer therapy. Labeling mabs with nuclides that emit a-particles is one approach for enhancing the selectivity of tumor cell irradiation. Other issues are to select the monoclonal antibody that serves to carry the radionuclide to the tumor target and the type of malignancy chosen as the target for radioimmunotherapy. The radioisotope used here is 213 Bi (half-life 45.6 min), which decays by the emission of alpha particles with high LET and short range ( % 80 mm). As a consequence, the relative biological effectiveness (RBE) is higher than that of the low-LET b-particle emitters currently used in clinical radioimmunotherapy. Several review articles have recently summarized the applications of alpha-emitting radionuclides for the treatment of disease. 26,43 -45 Previous in vivo work with a-particle emitters has been done with lymphoid tumors, which are accessible to the circulation, 40, 46 with injections of radiolabeled mab directly to the tumor site, 47 and with i.v. injection of 213 Bi-labelled mab to target micrometastases in lung. 48 In this laboratory, we have Targeted alpha therapy Y Li et al reported successful intra-lesional TAT for s.c. melanoma. 28 PSMA is a 750-amino acid, type 2 transmembrane glycoprotein expressed on the surface of prostate epithelial cells. It was originally defined by the monoclonal antibody 7E11, C5 and has been shown with genetic and protein studies to be highly prostate specific but with weak expression in the brain, salivary gland and small intestine. 14,16,49 -51 Several anti-PSMA antibodies have been developed against both intra-and extracellular epitopes. 52 Liu et al 17 first reported the binding of J591 mab to live cells and external epitopes of the PSMA molecule. The mab binds to LNCaP cells in vitro as well as to prostate epithelial cells. In addition, it reacts strongly with vascular endothelium in a variety of tumors, including prostate, lung, colon and breast. There is no reactivity with normal endothelium. 111 In-labeled 7E11.C5 antibody against the internal domain of PSMA has been applied to the in vivo imaging of occult prostate cancer lesions using the ProstaScint TM scan (Cytogen, Princeton, NJ). 53 PSMA peptides have also been employed as immunotherapeutic agents for prostate carcinoma treatment in Phase I and II clinical trials. 54, 55 These results indicate the potential use of this molecule in prostate carcinoma.
In the present study we have chosen PSMA, identified by the J591 mab, as our target for the AIC. The present system relies on the targeting of Bi-213 to LN3 cells and tumor vascular endothelium that express PSMA. Our present experiments demonstrate that J591 expression is strongly positive in LN3 cells, LN3 tumor cells and vascular endothelium in LN3 tumors. Furthermore, J591 mab can bind to viable LN3 cells, in agreement with the previous in vitro detection of PSMA expression in the LNCaP cell line. Our findings indicate that the s.c. LN3 xenograft is an appropriate model for investigating the efficacy of TAT because the results obtained would be likely to be applicable to a clinical trial. Our in vitro cell survival assay showed that LN3 prostate cancer cells were very sensitive to the inhibitory activity of AIC, in agreement with recent results by McDevitt et al. 32 The experiments described in this report demonstrate that 213 Bi-labeled a-particle-emitting immunoconjugates exhibit high levels of antigen-selective cytotoxicity, compared with non-specific AIC. Our investigations suggest that the mechanism by which the AIC mediates its anticancer activity is apoptosis or programmed cell death, of importance for the development and homeostasis of multi-cellular organisms. 56 Specific therapies have been designed to enhance the susceptibility of human cancers to undergo apoptosis. 57, 58 Previous investigators have reported that radiation can kill cells by inducing apoptosis, generating free oxygen species and causing DNA strand breaks. 59 -63 Two recent reports demonstrate that tumor necrosis factor-a and sphingosine could sensitize LNCaP cells to g-irradiation-induced apoptosis. 64, 65 In the present study, we showed that the AIC significantly increased the number of apoptotic cells in LN3 cells.
Our in vivo studies were designed to assess the efficacy of an injectable AIC against human prostate tumors grown in mice. Although the system does not directly model the clinical situation for human prostate cancer patients because the tumor is not growing in the prostate gland or as a metastasis in other organs, it may reflect the potential of the AIC treatment method for patients with micro-metastases and early stage secondary disease. Results show that a single local dose of 50 mCi of AIC at 2 days post-inoculation completely inhibited the growth of tumor, whereas non-specific AIC of the same activity had little effect ( Figure 5A ). At 2 days post-inoculation, the histological description of the pre-tumor has been reported for LNCap cells to be disorganized cell clusters and nodules of several thousand cells. 32 Thus only specific AIC is effective in killing prostate cancer cells and clusters of these cells at the pre-tumor stage. 
Targeted alpha therapy Y Li et al
Intralesional injection of 100 mCi of specific AIC completely regressed the growth of small tumors (volume < 100 mm 3 ). These results complement those recently reported by McDevitt et al, 32 who observed a significant improvement in intra-muscular tumor free time (54 days) with a similar AIC over non-specific (33 days) and untreated (31 days) mice.
The therapeutic efficacy of the AIC results in part from the induction of apoptosis in LN3 cells, which we have documented both in vitro and in vivo. Our histological data indicated that at 1 week post-AIC treatment, the number of apoptotic cells in LN3 tumors increased while the number of proliferating cells (using the Ki-67 marker) decreased; 3 weeks after treatment, sections from tumors treated with AIC revealed extensive necrosis, apoptosis and fibrosis involving approximately 50 -80% of tumor area.
The mechanism of tumor eradication is not clear. One explanation is that because LN3 tumors are very soft tumors and the cancer cells express high density PSMA, the AIC can easily diffuse after an intra-lesional injection and target the cancer cells. According to McDevitt et al, 32 the process of targeting is through internalization of the mab. The internalized 213 Bi-J591-PSMA complex accumulates in endosomes and the alpha radiation cause double strands break in DNA breakage. Another possible reason is that as the vascular endothelium in LN3 tumors expresses PSMA, AIC can target vascular endothelium, damage blood vessels, and inhibit new blood vessel formation. This could result in cell islands that cannot obtain enough nutrients and oxygen to proliferate and eventually become necrotic. We found some necrotic centres in the cellular islands from our treated sections. Larger tumors exhibited a growth reduction, but not control, after a single intra-lesional AIC treatment.
Conclusions
The present study demonstrates that our AIC selectively kills human prostate cancer cells in vitro and can completely inhibit or regress tumor growth in vivo. The mechanism of tumor regression is likely to involve targeting of tumor cells and vascular endothelium, and induction of apoptotic regression of androgen-independent LN3 prostate tumors. Small primary tumor lesions or small multiple metastatic sites in prostate cancer should be considered to be the most suitable targets for AIC. This study was performed in mice and control of the micrometastases by TAT for human prostate cancer remains problematic. However, TAT with 213 Bi-J591 provides a potentially effective therapy for patients with micrometastases after primary treatment or patients with localized small tumors recurring after therapy.
